Loading patent…
AssigneeThe Texas A&M University System
InventorsJoe A. Arosh, Sakhila K. Banu
Estimating the term…
The present invention describes the selective inhibition of prostaglandin receptors (PGE2), e.g., EP2 and EP4, by one or more inhibitors are selected from 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid and (4Z)-7-[(rel-1S,2S,5R)-5-((1,1′-Biphenyl-4-yl)methoxy)-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid and salts thereof as a potential therapeutic tool or to expand the spectrum of currently available treatment options for endometriosis and other chronic gynecological diseases in reproductive age women. PGE2 inhibition through novel cell signaling mechanisms identified by the present invention provides an effective and attractive therapeutic tool for treatment without compromising pregnancy and sex life in the women.
A method of treating one or more chronic gynecological diseases in a subject comprising the steps of:
A pharmaceutical composition for treating one or more chronic gynecological diseases in a subject comprising:
A method of treating endometriosis in one or more female subjects in an age group of 12 to 50 years in a subject comprising the steps of:
Dependencies are inferred from the claim text.